The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CO-Vidarabine     (6R)-10-[4-hydroxy-5- (hydroxymethyl)oxolan...

Synonyms: Oncopent, Coforin, Niapent, Vidarbine, CI-825, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Covidarabine


Psychiatry related information on Covidarabine


High impact information on Covidarabine


Chemical compound and disease context of Covidarabine


Biological context of Covidarabine


Anatomical context of Covidarabine


Associations of Covidarabine with other chemical compounds


Gene context of Covidarabine


Analytical, diagnostic and therapeutic context of Covidarabine


  1. Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). Spiers, A.S., Moore, D., Cassileth, P.A., Harrington, D.P., Cummings, F.J., Neiman, R.S., Bennett, J.M., O'Connell, M.J. N. Engl. J. Med. (1987) [Pubmed]
  2. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. Piro, L.D., Carrera, C.J., Carson, D.A., Beutler, E. N. Engl. J. Med. (1990) [Pubmed]
  3. Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. Ho, A.D., Thaler, J., Stryckmans, P., Coiffier, B., Luciani, M., Sonneveld, P., Lechner, K., Rodenhuis, S., Peetermans, M.E., deCataldo, F. J. Natl. Cancer Inst. (1990) [Pubmed]
  4. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. Döhner, H., Ho, A.D., Thaler, J., Stryckmans, P., Sonneveld, P., de Witte, T., Lechner, K., Lauria, F., Bödewadt-Radzun, S., Suciu, S. J. Natl. Cancer Inst. (1993) [Pubmed]
  5. Phase II investigation of pentostatin in multiple myeloma: a Southwest Oncology Group study. Grever, M.R., Crowley, J., Salmon, S., McGee, R., Kraut, E.H., Buys, S.S., Rivkin, S.E. J. Natl. Cancer Inst. (1990) [Pubmed]
  6. Deoxycoformycin antagonizes ischemia-induced neuronal degeneration. Phillis, J.W., O'Regan, M.H. Brain Res. Bull. (1989) [Pubmed]
  7. Role of adenosine in sleep in rats. Radulovacki, M. Reviews in clinical & basic pharmacology. (1985) [Pubmed]
  8. Expression of human adenosine deaminase in murine haematopoietic progenitor cells following retroviral transfer. Belmont, J.W., Henkel-Tigges, J., Chang, S.M., Wager-Smith, K., Kellems, R.E., Dick, J.E., Magli, M.C., Phillips, R.A., Bernstein, A., Caskey, C.T. Nature (1986) [Pubmed]
  9. Absence of adenosine deaminase activity in a mammalian cell line transformed by Rous sarcoma virus. Shipman, C., Drach, J.C. Science (1978) [Pubmed]
  10. Establishment of the DU.528 human lymphohemopoietic stem cell line. Kurtzberg, J., Bigner, S.H., Hershfield, M.S. J. Exp. Med. (1985) [Pubmed]
  11. Metabolites from apoptotic thymocytes inhibit thymopoiesis in adenosine deaminase-deficient fetal thymic organ cultures. Thompson, L.F., Van de Wiele, C.J., Laurent, A.B., Hooker, S.W., Vaughn, J.G., Jiang, H., Khare, K., Kellems, R.E., Blackburn, M.R., Hershfield, M.S., Resta, R. J. Clin. Invest. (2000) [Pubmed]
  12. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. Rivet-Bastide, M., Vandecasteele, G., Hatem, S., Verde, I., Bénardeau, A., Mercadier, J.J., Fischmeister, R. J. Clin. Invest. (1997) [Pubmed]
  13. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. Seto, S., Carrera, C.J., Kubota, M., Wasson, D.B., Carson, D.A. J. Clin. Invest. (1985) [Pubmed]
  14. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin. Saven, A., Piro, L.D. Ann. Intern. Med. (1993) [Pubmed]
  15. Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26. Eltzschig, H.K., Faigle, M., Knapp, S., Karhausen, J., Ibla, J., Rosenberger, P., Odegard, K.C., Laussen, P.C., Thompson, L.F., Colgan, S.P. Blood (2006) [Pubmed]
  16. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Kay, N.E., Geyer, S.M., Call, T.G., Shanafelt, T.D., Zent, C.S., Jelinek, D.F., Tschumper, R., Bone, N.D., Dewald, G.W., Lin, T.S., Heerema, N.A., Smith, L., Grever, M.R., Byrd, J.C. Blood (2007) [Pubmed]
  17. Neurotoxicity of purine analogs: a review. Cheson, B.D., Vena, D.A., Foss, F.M., Sorensen, J.M. J. Clin. Oncol. (1994) [Pubmed]
  18. The erythrocyte as instigator of inflammation. Generation of amidated C3 by erythrocyte adenosine deaminase. Hostetter, M.K., Johnson, G.M. J. Clin. Invest. (1989) [Pubmed]
  19. Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients. Steis, R.G., Urba, W.J., Kopp, W.C., Alvord, W.G., Smith, J.W., Longo, D.L. J. Natl. Cancer Inst. (1991) [Pubmed]
  20. Extracellular adenosine induces apoptosis of human arterial smooth muscle cells via A(2b)-purinoceptor. Peyot, M.L., Gadeau, A.P., Dandré, F., Belloc, I., Dupuch, F., Desgranges, C. Circ. Res. (2000) [Pubmed]
  21. Clinical pharmacology of deoxycoformycin. Major, P.P., Agarwal, R.P., Kufe, D.W. Blood (1981) [Pubmed]
  22. Initial rate kinetics and evidence for duality of mediated transport of adenosine, related purine nucleosides, and nucleoside analogues in L1210 cells. Chello, P.L., Sirotnak, F.M., Dorick, D.M., Yang, C.H., Montgomery, J.A. Cancer Res. (1983) [Pubmed]
  23. Mechanisms of lymphocytotoxicity induced by extracorporeal photochemotherapy for cutaneous T cell lymphoma. Marks, D.I., Rockman, S.P., Oziemski, M.A., Fox, R.M. J. Clin. Invest. (1990) [Pubmed]
  24. Cerebrospinal fluid levels of 2'-deoxycoformycin after systemic administration in monkeys. Blatt, J., Venner, P.M., Riccardi, R., Cohen, L.F., Gangji, D., Glazer, R.I., Poplack, D.G. J. Natl. Cancer Inst. (1982) [Pubmed]
  25. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. Carrera, C.J., Terai, C., Lotz, M., Curd, J.G., Piro, L.D., Beutler, E., Carson, D.A. J. Clin. Invest. (1990) [Pubmed]
  26. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia. Prentice, H.G., Smyth, J.F., Ganeshaguru, K., Wonke, B., Bradstock, K.F., Janossy, G., Goldstone, A.H., Hoffbrand, A.V. Lancet (1980) [Pubmed]
  27. Decreased methionine synthesis in purine nucleoside-treated T and B lymphoblasts and reversal by homocysteine. Boss, G.R., Pilz, R.B. J. Clin. Invest. (1984) [Pubmed]
  28. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Nieva, J., Bethel, K., Saven, A. Blood (2003) [Pubmed]
  29. Rearrangement of both immunoglobulin and T-cell receptor genes in a prolymphocytic variant of hairy cell leukemia patient resistant to interferon-alpha. Giardina, S.L., Young, H.A., Faltynek, C.R., Jaffe, E.S., Clark, J.W., Steis, R.G., Urba, W.J., Mathieson, B.J., Gralnick, H., Lawrence, J. Blood (1988) [Pubmed]
  30. Clinical pharmacology of 9-beta-D-arabinofuranosyladenine in combination with 2'-deoxycoformycin. Agarwal, R.P., Blatt, J., Miser, J., Sallan, S., Lipton, J.M., Reaman, G.H., Holcenberg, J., Poplack, D.G. Cancer Res. (1982) [Pubmed]
  31. Effect of deoxycoformycin and Val-boroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase. Jeanfavre, D.D., Woska, J.R., Pargellis, C.A., Kennedy, C.A., Prendergast, J., Stearns, C., Reilly, P.L., Barton, R.W., Bormann, B.J. Biochem. Pharmacol. (1996) [Pubmed]
  32. Activation of apoptosis in early mouse embryos by 2'-deoxyadenosine exposure. Gao, X., Blackburn, M.R., Knudsen, T.B. Teratology (1994) [Pubmed]
  33. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Bouma, M.G., van den Wildenberg, F.A., Buurman, W.A. Am. J. Physiol. (1996) [Pubmed]
  34. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Steis, R.G., Marcon, L., Clark, J., Urba, W., Longo, D.L., Nelson, D.L., Maluish, A.E. Blood (1988) [Pubmed]
  35. Adenosine deaminase inhibition attenuates microvascular dysfunction and improves survival in sepsis. Cohen, E.S., Law, W.R., Easington, C.R., Cruz, K.Q., Nardulli, B.A., Balk, R.A., Parrillo, J.E., Hollenberg, S.M. Am. J. Respir. Crit. Care Med. (2002) [Pubmed]
  36. Efficacy of 2'-deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group. Johnston, J.B., Eisenhauer, E., Corbett, W.E., Scott, J.G., Zaentz, S.D. J. Natl. Cancer Inst. (1988) [Pubmed]
  37. Protection of the stunned myocardium. Selective nucleoside transport blocker administered after 20 minutes of ischemia augments recovery of ventricular function. Abd-Elfattah, A.S., Ding, M., Dyke, C.M., Wechsler, A.S. Circulation (1993) [Pubmed]
  38. Animal model for immune dysfunction associated with adenosine deaminase deficiency. Tedde, A., Balis, M.E., Ikehara, S., Pahwa, R., Good, R.A., Trotta, P.P. Proc. Natl. Acad. Sci. U.S.A. (1980) [Pubmed]
WikiGenes - Universities